Controls and prevents bleeds with one or two infusions.
92.5% of bleeds are treated successfully on demand with one or two infusions.
The median annualized bleed rate for all bleeding episodes is 1.9 and 45.7% subject said no bleeding episodes.
Administered as an intravenous infusion.
Indicated for the control and prevention of bleeding episodes in patients with hemophilia A and for surgical prophylaxis in such patients.
Does not contain von Willebrand factor and is not useful in von Willebrand’s disease.
Should be monitored for the development of inhibitors.
Most common adverse reaction is headache, fever, nausea, vomiting, diarrhea, and weakness.